A phase IV study of Apricity C.A.R.E. program for Cancer Adverse events Rapid Evaluation to improve treatment outcomes of ethnic/racial minority non-small cell lung cancer (NSCLC) patients receiving immunotherapy

Go Back to All Clinical Trials

A phase IV study of Apricity C.A.R.E. program for Cancer Adverse events Rapid Evaluation to improve treatment outcomes of ethnic/racial minority non-small cell lung cancer (NSCLC) patients receiving immunotherapy

Brief description of study

Clinical Study Identifier: s22-01442

ClinicalTrials.gov Identifier: NCT05812274

Principal Investigator: Vamsidhar Velcheti.

Other Investigators: Samantha VanMaanen, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Sally Lau, Joshua K Sabari, David Mendoza, Natalia Cherkassky, Melissa L Martinez.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies